GHRP-6
Research OnlyAlso known as: Growth Hormone Releasing Peptide-6, SKF-110679, Growth Hormone-Releasing Hexapeptide
A first-generation growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Less selective than newer alternatives with effects on cortisol and prolactin. Historically significant as the peptide that led to ghrelin discovery. Cuban CIGB leads global cytoprotective research. Not approved for any indication.
Research Statistics
GH secretagogue with similar evidence to GHRP-2; multi-country research base.
Research Dossier
Overview
What is GHRP-6 and what does the research say?
Mechanism of Action
GHRP-6 stimulates growth hormone release by activating the ghrelin receptor (GHS-R1a), the same receptor that responds to the endogenous “hunger hormone” ghrelin. Discovered in 1984 before ghrelin itself was identified, GHRP-6 is historically significant as the compound that led to the discovery of the entire ghrelin/GHS system through “reverse pharmacology.”
How It Works (Simplified)
GHRP-6 acts as a potent signal for growth hormone release through multiple interconnected pathways:
Binds to GHS-R1a on pituitary somatotrophs, triggering calcium release and direct GH secretion independent of cAMP pathways.
Acts primarily at the hypothalamus to stimulate GHRH neurons, creating a synergistic amplification of growth hormone release.
Activates NPY/AgRP neurons in the arcuate nucleus, producing strong orexigenic (hunger-inducing) effects via the same pathway as natural ghrelin.
Binds to CD36 scavenger receptor on cardiomyocytes, potentially providing GH-independent cytoprotective effects through Bcl-2 upregulation.
Scientific Pathways
Primary GH Release Pathway (Gq/11 Signaling)
GHRP-6 → GHS-R1a activation → Gq/11 protein → PLC activation
↓
IP3 production
↓
Ca²⁺ release from ER
↓
GH vesicle exocytosisHypothalamic Amplification Pathway (GHRH Synergism)
GHRP-6 → Hypothalamic GHS-R1a → GHRH neuron activation → Pituitary GHRH-R
↓
Amplified GH releaseKey Research: Pandya et al. (1998) demonstrated that GHRP-6 requires endogenous GHRH for maximal effect, and patients with hypothalamopituitary disconnection show blocked responses. PMID:9543138
Important Limitations
- Less selective than newer GHRPs (ipamorelin) - also increases cortisol and prolactin
- Strong appetite stimulation may be undesirable for many applications
- No long-term human safety data available
- Cytoprotective effects remain preclinical only despite promising animal data
- Human pharmacokinetics characterized but optimal therapeutic dosing unknown
- Not approved by any regulatory agency; WADA prohibited substance
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Rapid GH release begins within minutes of administration. Peak GH response typically occurs at 15-30 minutes post-injection based on human PD studies.
Transient increases in cortisol and ACTH. Appetite stimulation begins. Mild flushing may occur in some subjects.
GH levels return toward baseline. Elimination half-life approximately 2.5 hours. Distribution half-life only 7.6 minutes indicates rapid tissue uptake.
No long-term human data available. Unknown whether tachyphylaxis develops. Theoretical concerns about HPA axis effects and chronic appetite stimulation.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate GHRP-6 product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining GHRP-6 with other peptides. Based on published research and mechanistic considerations.
CJC-1295
SynergisticWell-established GHRH+GHRP synergy. GHRP-6 initiates GH pulse via ghrelin receptor while CJC-1295 amplifies release via GHRH receptor. Greater GH release than either alone.
Sermorelin
SynergisticClassic GHRH+GHRP combination. Sermorelin (GHRH analog) and GHRP-6 act through complementary pathways with synergistic effect on GH secretion.
Ipamorelin
CompatibleBoth are GHRPs acting on ghrelin receptor. Ipamorelin is more selective with cleaner profile. No clear rationale for combining same-mechanism agents.
GHRP-2
CompatibleSame receptor target. GHRP-2 is more potent but both affect cortisol/prolactin. No established benefit to combining.
MK-677
CompatibleBoth stimulate GH via ghrelin pathway. MK-677 provides 24-hour elevation. May be redundant but mechanisms differ slightly.
BPC-157
CompatibleCuban CIGB research explores cytoprotective combinations. Different mechanisms; no known contraindications.
Semaglutide
CautionGHRP-6 strongly stimulates appetite via ghrelin signaling, which may counteract semaglutide's appetite-suppressing effects. Also monitor glucose.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare GHRP-6
GHRP-6 Calculators
Related Peptides
CJC-1295
DAC:GRF, Modified GRF 1-29, Tetrasubstituted GRF
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Limited clinical development; not approved for any indication.
Follistatin
FST, FS-344, FS-315 +1 more
An endogenous glycoprotein that inhibits myostatin and activin signaling, potentially allowing muscle growth beyond genetic limits. Gene therapy trials for muscular dystrophy show promise, but injectable peptide forms remain unapproved and understudied in humans.
Human Chorionic Gonadotropin (hCG)
hCG, Choriogonadotropin, Pregnyl +5 more
A glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
HMG
Human Menopausal Gonadotropin, Menotropins, hMG +4 more
A urinary-derived glycoprotein hormone preparation containing both FSH and LH in approximately 1:1 ratio, FDA-approved for female infertility (ovulation induction, ART) and male hypogonadotropic hypogonadism. First used clinically in 1961 by Bruno Lunenfeld, HMG enabled the birth of the first American IVF baby in 1981 and remains a cornerstone of fertility medicine with over 60 years of clinical experience. Highly purified preparations (HP-hMG) demonstrate comparable or slightly superior live birth rates compared to recombinant FSH in IVF.
IGF-1 LR3
Long R3 IGF-1, LR3-IGF-1, Insulin-like Growth Factor 1 Long R3
A modified form of IGF-1 with an extended half-life due to reduced binding protein affinity. Used primarily in research for muscle growth and metabolic effects. Not approved for human use; significant safety concerns exist.
Kisspeptin
KISS1, Metastin, Kisspeptin-54 +3 more
An endogenous neuropeptide that serves as the master regulator of reproductive function. Acts upstream of GnRH to control puberty, fertility, and the menstrual cycle. Under clinical investigation as a safer IVF trigger and treatment for hypothalamic amenorrhea. Pioneering research led by Imperial College London.